These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 19591966)

  • 1. The emerging role of serotonin (5-hydroxytryptamine) in the skeleton and its mediation of the skeletal effects of low-density lipoprotein receptor-related protein 5 (LRP5).
    Warden SJ; Robling AG; Haney EM; Turner CH; Bliziotes MM
    Bone; 2010 Jan; 46(1):4-12. PubMed ID: 19591966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Skeletal effects of serotonin (5-hydroxytryptamine) transporter inhibition: evidence from in vitro and animal-based studies.
    Warden SJ; Haney EM
    J Musculoskelet Neuronal Interact; 2008; 8(2):121-32. PubMed ID: 18622081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Where Wnts went: the exploding field of Lrp5 and Lrp6 signaling in bone.
    Williams BO; Insogna KL
    J Bone Miner Res; 2009 Feb; 24(2):171-8. PubMed ID: 19072724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LRP5 mutations in osteoporosis-pseudoglioma syndrome and high-bone-mass disorders.
    Levasseur R; Lacombe D; de Vernejoul MC
    Joint Bone Spine; 2005 May; 72(3):207-14. PubMed ID: 15850991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. When the gut talks to bone.
    Long F
    Cell; 2008 Nov; 135(5):795-6. PubMed ID: 19041744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update in serotonin and bone.
    Bliziotes M
    J Clin Endocrinol Metab; 2010 Sep; 95(9):4124-32. PubMed ID: 20823465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutations in LRP5 cause primary osteoporosis without features of OI by reducing Wnt signaling activity.
    Korvala J; Jüppner H; Mäkitie O; Sochett E; Schnabel D; Mora S; Bartels CF; Warman ML; Deraska D; Cole WG; Hartikka H; Ala-Kokko L; Männikkö M
    BMC Med Genet; 2012 Apr; 13():26. PubMed ID: 22487062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum.
    Yadav VK; Ryu JH; Suda N; Tanaka KF; Gingrich JA; Schütz G; Glorieux FH; Chiang CY; Zajac JD; Insogna KL; Mann JJ; Hen R; Ducy P; Karsenty G
    Cell; 2008 Nov; 135(5):825-37. PubMed ID: 19041748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N-cadherin interacts with axin and LRP5 to negatively regulate Wnt/beta-catenin signaling, osteoblast function, and bone formation.
    Haÿ E; Laplantine E; Geoffroy V; Frain M; Kohler T; Müller R; Marie PJ
    Mol Cell Biol; 2009 Feb; 29(4):953-64. PubMed ID: 19075000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential role for therapies targeting DKK1, LRP5, and serotonin in the treatment of osteoporosis.
    Zhang W; Drake MT
    Curr Osteoporos Rep; 2012 Mar; 10(1):93-100. PubMed ID: 22210558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Wnt co-receptor LRP5 is essential for skeletal mechanotransduction but not for the anabolic bone response to parathyroid hormone treatment.
    Sawakami K; Robling AG; Ai M; Pitner ND; Liu D; Warden SJ; Li J; Maye P; Rowe DW; Duncan RL; Warman ML; Turner CH
    J Biol Chem; 2006 Aug; 281(33):23698-711. PubMed ID: 16790443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Depression, selective serotonin reuptake inhibitors, and osteoporosis.
    Bab I; Yirmiya R
    Curr Osteoporos Rep; 2010 Dec; 8(4):185-91. PubMed ID: 20809204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 1,25-Dihydroxyvitamin D3 regulates the expression of low-density lipoprotein receptor-related protein 5 via deoxyribonucleic acid sequence elements located downstream of the start site of transcription.
    Fretz JA; Zella LA; Kim S; Shevde NK; Pike JW
    Mol Endocrinol; 2006 Sep; 20(9):2215-30. PubMed ID: 16613987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The genetics of low-density lipoprotein receptor-related protein 5 in bone: a story of extremes.
    Balemans W; Van Hul W
    Endocrinology; 2007 Jun; 148(6):2622-9. PubMed ID: 17395706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathogenic mutations and polymorphisms in the lipoprotein receptor-related protein 5 reveal a new biological pathway for the control of bone mass.
    Ferrari SL; Deutsch S; Antonarakis SE
    Curr Opin Lipidol; 2005 Apr; 16(2):207-14. PubMed ID: 15767861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lrp5 and bone formation : A serotonin-dependent pathway.
    Yadav VK; Ducy P
    Ann N Y Acad Sci; 2010 Mar; 1192():103-9. PubMed ID: 20392224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LRP5, Bone Mass Polymorphisms and Skeletal Disorders.
    Littman J; Yang W; Olansen J; Phornphutkul C; Aaron RK
    Genes (Basel); 2023 Sep; 14(10):. PubMed ID: 37895195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic analysis of Lrp5 function in osteoblast progenitors.
    Yadav VK; Arantes HP; Barros ER; Lazaretti-Castro M; Ducy P
    Calcif Tissue Int; 2010 May; 86(5):382-8. PubMed ID: 20333369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel LRP5 missense mutation in a patient with a high bone mass phenotype results in decreased DKK1-mediated inhibition of Wnt signaling.
    Balemans W; Devogelaer JP; Cleiren E; Piters E; Caussin E; Van Hul W
    J Bone Miner Res; 2007 May; 22(5):708-16. PubMed ID: 17295608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lrp5 functions in bone to regulate bone mass.
    Cui Y; Niziolek PJ; MacDonald BT; Zylstra CR; Alenina N; Robinson DR; Zhong Z; Matthes S; Jacobsen CM; Conlon RA; Brommage R; Liu Q; Mseeh F; Powell DR; Yang QM; Zambrowicz B; Gerrits H; Gossen JA; He X; Bader M; Williams BO; Warman ML; Robling AG
    Nat Med; 2011 Jun; 17(6):684-91. PubMed ID: 21602802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.